Dr. Wolchok on Remaining Questions Regarding Immunotherapies in Melanoma

Jedd D. Wolchok, MD, PhD
Published: Tuesday, Jan 13, 2015

Jedd D. Wolchok, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses remaining questions regarding immunotherapies for the treatment of melanoma.

Despite success, there are several questions that remain. One crucial area, Wolchok says, is the need identify biomarkers to enrich patient populations.

Research is also focusing on how to form rational, potent, and safe combinations of immunotherapies. Wolchok says research is also being conducted looking at combining immunotherapies and targeted therapies. This area is particularly important, as some targeted pathway inhibitors could have a positive or negative effect on immune cells, in addition to having activity against cancer cells.

Jedd D. Wolchok, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses remaining questions regarding immunotherapies for the treatment of melanoma.

Despite success, there are several questions that remain. One crucial area, Wolchok says, is the need identify biomarkers to enrich patient populations.

Research is also focusing on how to form rational, potent, and safe combinations of immunotherapies. Wolchok says research is also being conducted looking at combining immunotherapies and targeted therapies. This area is particularly important, as some targeted pathway inhibitors could have a positive or negative effect on immune cells, in addition to having activity against cancer cells.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x